Genexol PM Injection
Marketer
Lupin Ltd
Salt Composition
Paclitaxel (100mg)
Overview Genexol PM Injection
Oncoxin, administered intravenously by a healthcare provider, combats breast, pancreatic, and non-small cell lung cancers. Dosage and frequency are determined by your physician based on your specific condition and may vary. Adhere strictly to your doctor's prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may not be apparent for weeks or months; discontinue only under your doctor's guidance. Common side effects include nausea, vomiting, and fatigue. Serious side effects like edema (swelling of hands and face), alopecia (hair loss), and weight increase are possible. Concomitant medications may mitigate these. Report any unusual bruising, bleeding, pharyngitis (sore throat), oral ulcers, or pyrexia (fever) immediately. Oncoxin can suppress blood cell production, increasing infection risk. Regular blood tests monitoring blood counts and liver function are vital. Prior to treatment, disclose any cardiac, hepatic (liver), or renal (kidney) conditions, and all current medications, including antibiotics, as drug interactions are possible. This medication is contraindicated during pregnancy and lactation. Reliable contraception for both partners is crucial throughout treatment to prevent conception.
Uses of Genexol PM Injection
Cancers affecting the breast, lung (non-small cell type), and pancreas.
Major Benefits of Genexol PM Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Genexol PM Injection:
- Nausea
- Vomiting
- Weakness
- Low blood platelets
- Rash
- Upper respiratory tract infection
- Urinary tract infection
- Bleeding
- Anemia (low number of red blood cells)
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Hair loss
- Decreased blood pressure
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Diarrhea
- Decreased white blood cell count (neutrophils)
How to use Genexol PM Injection:
Administering this medication will be done by your healthcare provider. Self-medication is strictly prohibited.
How Genexol PM Injection works:
Genexol PM Injection is a cancer therapeutic agent. Its mechanism of action involves disrupting microtubule networks, essential for cancer cell proliferation. This inhibits cancer cell growth, ultimately leading to their demise.
SAFETY ADVICE
AlcoholUNSAFE
Combining Genexol PM Injection and alcohol is contraindicated.
PregnancyCONSULT YOUR DOCTOR
Administering Genexol PM Injection during pregnancy poses a confirmed risk to the fetus. Therefore, its use is contraindicated. Nevertheless, in exceptional, life-threatening circumstances, a physician might deem its use justifiable if the potential benefits outweigh the known hazards. Physician consultation is mandatory.
Breast feedingUNSAFE
Administration of Genexol PM Injection is contraindicated while breastfeeding due to potential infant toxicity.
DrivingUNSAFE
Driving ability may be impaired by Genexol PM Injection side effects. While there's no inherent prohibition against driving between treatment cycles, the medication's alcohol content suggests caution regarding driving.
KidneySAFE IF PRESCRIBED
Genexol PM Injection poses no known safety risk to individuals with kidney conditions; dose modification isn't typically necessary. Nevertheless, consultation with a physician is advisable for patients with pre-existing kidney disease.
LiverCAUTION
Patients with liver impairment should receive Genexol PM Injection cautiously, potentially requiring dosage modification. Severe hepatic dysfunction contraindicates Genexol PM Injection; physician consultation is advised.
What if you forget to take Genexol PM Injection :
NA
Facts to Know About Genexol PM Injection
| Label | Value |
|---|---|
| Chemical Classification | Taxane-Based Drugs |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Action Class | Taxanes: Antimicrotubule Agents |
3,018 People bought this recently